BrightSpring Health 服务
估值 各估值倍数与自身5年区间的对比
同业对比 Health Information Services
| 公司 | 市值 | 市盈率(TTM)i | 市净率i | 股息率i |
|---|---|---|---|---|
| BrightSpring Health 服务 (BTSG) | 12.04B | 36.89 | 5.88 | 0.00% |
| Veeva Systems (VEEV) | 50.25B | 50.88 | 6.76 | 0.00% |
| Tempus AI (TEM) | 11.68B | -44.94 | 26.24 | 0.00% |
| Hinge Health (HNGE) | 8.00B | 74.11 | 23.24 | 0.00% |
| HealthEquity (HQY) | 7.61B | 33.22 | 3.83 | 0.00% |
| Doximity (DOCS) | 5.52B | 36.87 | 6.03 | 0.00% |
StockVane 追踪范围内同行业的其他公司。
Morningstar
当前股价高于晨星合理价值估算15.7%。
合理价值
BrightSpring Health Services Inc earns a 2-star quantitative star rating, indicating our belief that this share class is a somewhat unattractive choice, and investors should look elsewhere for more fruitful opportunities. The stock currently trades at a 21% premium over our quantitative fair value estimate of $51.30 per share; however, this estimate should be taken with a pinch of salt due to its high uncertainty rating.
The firm's valuation metrics undermine our fair value estimate. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. Reflecting the firm's valuation is its book value yield of 17.2%, which sits in the bottom 20% compared with peers globally. The market value of this company's shares looks expensive relative to the book (accounting) value of equity, which contributes to our view that shares are expensive.
Conversely, the firm's solid growth is reassuring. Consistent revenue and earnings growth indicates a company's potential for increased market share and profitability. The firm's EPS 5-year growth of 43.7%, for example, sits in the top 10% compared with peers globally. The robust five-year track record of EPS growth is reason to be optimistic about the firm's shares. Despite our unfavorable price/fair value ratio, this characteristic is a positive attribute.
In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance may signify a bull trap, in light of other detractors from our model.
经济护城河
The company's narrow quantitative moat rating indicates it could outearn its cost of capital and maintain robust margins for 10 years or longer. In addition, the company's moderate financial health score is decent and doesn't seriously concern us with regard to financial distress.
作者:Quantitative Equity Report
报价时间 2026-10-16 20:02:31 · 仅供参考,不构成投资建议,也未考虑您的具体情况。
BrightSpring Health 服务 讨论区 0 条评论